#United States #San Francisco #Kodiak Sciences #retinal diseases #glaucoma

Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025

Kodiak Sciences, a pioneering biopharmaceutical company based in Palo Alto, California, is gearing up to present at the upcoming Glaucoma 360 New Horizons Forum scheduled for February 7, 2025, in San Francisco, CA. The company will showcase its innovative strategies for treating glaucoma, a debilitating condition affecting an estimated 76 million people worldwide, making it the leading cause of irreversible blindness.

Glaucoma primarily presents as an optic neuropathy that progressively damages the optic nerve, leading to partial or total vision loss. Traditionally, glaucoma treatments have aimed to reduce elevated intraocular pressure (IOP), the main modifiable risk factor associated with the disease. However, recent research indicates that neuroinflammation significantly contributes to optic neuropathy, prompting a reevaluation of therapeutic strategies.

Dolly Chang, M.D., Ph.D., Chief Scientific Officer of Kodiak Sciences, explained, "At Kodiak, we are utilizing our unique Antibody Biopolymer Conjugate Drug (ABCD) platform to develop a novel therapy that not only targets neuroinflammation but also works to lower IOP. This dual-action approach could potentially revolutionize the treatment landscape for glaucoma by addressing both the inflammation driving optic nerve damage and the pressure-related aspect of the condition."

The groundbreaking therapy will be presented under the title "Addressing Optic Neuropathy Through Neuroinflammation Modulation and IOP Lowering with the ABCD Platform: A Polymedicine Approach to Glaucoma". This innovative dual-mechanism drug aims to directly target the NLRP3 inflammasome, a critical component involved in neuroinflammation, while simultaneously incorporating a molecule designed to lower eye pressure. With quarterly dosing designed to provide a longer-lasting effect, Kodiak's investigational therapy represents a significant leap forward in glaucoma care.

Dr. Chang further stated, "Our goal with the ABCD platform is to redefine glaucoma treatment by delivering next-generation therapies that not only aim for effective biological intervention but also lead to improved patient outcomes over extended periods."

The presentation at the Glaucoma 360 New Horizons Forum is part of a broader session titled "Beyond IOP Targeting: Neuroprotection and Vision Restoration", running from 10:45 to 11:55 a.m. PST. Slides from the presentation will be accessible on Kodiak's official website shortly after the event.

Kodiak Sciences is dedicated to combating a wide range of retinal diseases through innovative bioengineering. Their lead investigational treatment, tarcocimab, aims to tackle prevalent retinal vascular diseases and is currently being evaluated in pivotal Phase 3 trials. This focus is complemented by KSI-501 and KSI-101, both of which further showcase the company’s commitment to creating effective, long-term solutions for patients suffering from these debilitating conditions.

As Kodiak develops its pipeline of therapies and conducts essential research aimed at solving unmet medical needs in retinal health, they remain at the forefront of addressing pressing issues related to vision disorders. By merging protein chemistry with innovative drug delivery techniques, Kodiak Sciences is poised to make critical contributions to the field of ophthalmology.

To learn more about Kodiak Sciences and their upcoming presentation, visit their website at www.kodiak.com.